
Browsing restrictions can be lifted for a fee.
Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name. The company also provides 7-day long-acting pain reliever injections under the Naldebain brand name. In addition, it offers pressure injectable implantable port kits under the POLYSITE brand; and universal linear cutting staplers under the easyEndo brand name. The company was founded in 2008 and is based in New Taipei City, Taiwan.
The most recent financial report for 安美得 (7575) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7575's short-term business performance and financial health. For the latest updates on 7575's earnings releases, visit this page regularly.
According to historical valuation range analysis, 安美得 (7575)'s current price-to-earnings (P/E) ratio is 18.96, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 安美得 (7575) reported an Operating Profit of 31M with an Operating Margin of 7.72% this period, representing a decline of 43.4% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 安美得 (7575) announced revenue of 401.51M, with a Year-Over-Year growth rate of 3.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 安美得 (7575) held Total Cash and Cash Equivalents of 103.81M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 安美得 (7575) achieved the “three margins increasing” benchmark, with a gross margin of 66.32%%, operating margin of 7.72%%, and net margin of 1.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7575's profit trajectory and future growth potential.
According to the past four quarterly reports, 安美得 (7575)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.23. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
安美得 (7575)'s Free Cash Flow (FCF) for the period is 62.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 97.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
7575
安美得
-4.61%
(-0.05)